As the number of diagnosed cases of COVID-19 continues to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization.
Seemingly in response to global uncertainty over the coronavirus outbreak, the stock markets have plunged, numerous conferences are being canceled and biopharma companies are taking action.
Three employees of Boston-based Biogen tested positive for the novel coronavirus.
Japanese drug manufacturer Takeda Pharmaceutical indicated that the company is attempting to develop a drug based on the blood of patients who recovered from COVID-19.
One key issue for healthcare brands that many of us know about and have seen firsthand is keeping marketing and sales teams in complete alignment as the brand message is developed and then rolled out in the field. In the race to get positive marketplace momentum going there can be a disconnect that develops in what we call the “passing of the baton” from marketing to sales. It’s when, even after all the work, time, creativity, analysis, and testing that goes into brand development, somehow a gap arises, or the timing is off as the proverbial brand “baton” is passed to the sales force.
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name: COVID-19. The most recent figures indicate there are more than 45,000 infections worldwide and the virus has killed more than 1,100 people.
In honor of Black History Month, BioSpace highlighted 10 African-American leaders who have prominent roles in the life sciences and biopharmaceutical industry.
In a first-of-its-kind effort, the Biotechnology Innovation Organization (BIO) conducted a survey that attempts to dive into diversity within the pharmaceutical and biotech industry.
Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
